Group items tagged

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this FOA is to establish a Cancer Immunotherapy Consortium (CIC) composed of organ site-specific Cancer Immunotherapy Research Projects as a component of the Immuno-Oncology Translation Network (IOTN). The CIC will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor progression, and evaluating new or improved immunotherapeutic strategies (including combinations with standard or other therapies) resulting in durable anti-cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints.

1. Basic Science of Gene Therapy for Hemophilia * Basic science, tropism, transduction efficiency & tolerability of Adeno associated virus (AAV) * AAV antibody seroprevalence, titer- assessment, reduction & tolerance * Role of immunosuppression in managing immune response and potential retreatment * Effect of Gene Therapy on liver biology 2. Basic Science of TFPI & Anti-TFPI Monoclonal Antibodies * Basic biology of TFPI interactions with Protein C, ATIII & Protein S * Cross talk among regulators (e.g., Protein S being a co-factor for both Protein C and TFPI) * Role of different TFPI pools in regulation of coagulation * Impact of concomitant treatments (especially antifibrinolytics) added to anti-TFPI on the physiology of hemostasis * Note: Pfizer will not supply study drug 3. Burden of disease: Clinical Hemophilia A and B * Natural history of hemophilia and adherence to current standard of care * Arthropathy: presence, development, clinical burden & joint damage in hemophilia * Patient experiences with hemophilia, treatment preferences and quality of care * Quality of Life/Work analysis and cost of care in Hemophilia

The National Center for Complementary and Integrative Health (NCCIH) announces the availability of funds for Administrative Supplements or Urgent Competitive Revisions to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NCCIH is particularly interested in projects focusing on the therapeutic and/or mechanistic effects on SARS-CoV-2/COVID-19 of natural product-based complementary remedies including, but not limited to: herbal therapies, vitamins, supplements, probiotics, microbial therapies, and Chinese medicine herbal preparations.

The purpose of this FOA is to solicit applications for an Epilepsy Center without Walls (CWOW) focused on multidisciplinary, collaborative research to further the development of disease modifying or prevention therapies for epilepsy.

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that unique mechanisms contribute to the development of obesity in PWH versus people without HIV. Alterations in fat tissue biology may be central to these differences. This FOA seeks applications to elucidate the underlying mechanisms of how HIV and antiretroviral drugs used for therapy or pre-exposure prophylaxis contribute to the development of obesity and alter adipocyte and adipose tissue function as well as the effects of these processes on metabolic and physiological processes within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell replacement therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for T1D treatment.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell replacement therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for T1D treatment.

ntiretroviral therapy has been recommended for all persons living with HIV since 2012. However, in 2014, among persons with diagnosed HIV infection, 57.9% of all persons were virally suppressed and 48.1% of youth were virally suppressed (https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-22-2.pdf ). Insurers have information on clinical encounters which provide them with diagnoses codes. They also have information on pharmacy claims data and can assess if persons with a diagnosis of HIV are receiving antiretroviral (ARV) drugs.

In celebration of the Human-Canine Bond, the Fund awards five scholarships per year, totaling $10,000 annually, payable as tuition assistance to accredited institutions to full-time students enrolled in courses of study that contribute to the well-being of dogs and responsible pet ownership. Individuals pursuing studies in veterinary medicine, veterinary technology, physical therapy, animal care, animal behavior, grooming and training, may be eligible for this grant.

This initiative will support research projects that implement and test comprehensive service approaches to engage and retain youth and young adults (age 12 - 25 years) from health disparity populations in the HIV Treatment Cascade, which includes diagnosis, linkage to care, engagement in care, retention in care, initiation of antiretroviral therapy (ART), and achievement of viral suppression.   

The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK with the SBIR program. SBIR Phase I projects under this FOA supportpreliminary steps in the process for lead optimization or preclinical development of therapeutics. SBIR Phase II supports lead optimization and preclinical development of lead candidates, and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a SBIR Phase II or IIB project.

he overall goal of this initiative is to enhance our understanding of fundamental biological mechanisms involved in disease conditions that disproportionately affect health disparity populations and develop therapies or interventions that can directly or demonstrably contribute to the reduction or elimination of health disparities. This funding opportunity announcement (FOA) solicits applications to conduct: 1. Biological and genetic research to explore disease mechanisms or pathways that influence health outcomes in minority and health disparity populations. 2. Clinical and translational research linking basic science discovery with effective treatment or clinical practice to improve health outcomes in minority and health disparity populations. Projects investigating the etiology, physiology, genetic risk factors, molecular pathways, gene-environmental interactions, pharmacogenomic and personalized medicine in health disparity populations are particularly encouraged.

The overall goal of this funding opportunity announcement (FOA) is to utilize a district model approach to scale-up HIV prevention and treatment interventions to create an AIDS free generation in four districts in Lesotho. This will be achieved by implementing interventions to expand coverage of provider-initiated testing and counseling (PITC) and linkage into care services and treatment; reduce the rate of mother to child transmission to less than 5% and keep the mother-baby pairs alive; increase coverage of HIV treatment both to reduce AIDS-related mortality and to enhance HIV prevention; ensure that all TB-HIV co-infected people are initiated on antiretroviral therapy (ART) and retained in care; and strengthen the capacity of District Health Management Teams (DHMT) to routinely deliver high quality HIV programs in each district. The goal and activities of this FOA are in alignment with the Lesotho National HIV/AIDS Strategic Plan (NSP) . The four service districts will be Leribe, Berea, Quithing, and Qacha's Nek, which have a combined estimated population of 750,000.

i. Purpose: The purpose of these activities is to support the goals of the HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis, 2014-2016 (available at http://aids.gov/pdf/viral-hepatitis-action-plan.pdf) by ensuring Hepatitis B-infected pregnant women are identified so that their infants can receive timely post-exposure prophylaxis, improvements in post-vaccination serologic testing to improve efficiencies, and data collection to assess infant outcomes ii. Outcomes: Increased identification of Hepatitis B-infected pregnant women; increased rates of post-vaccination serologic testing among infants born to Hepatitis B-infected pregnant women; and assessment of factors associated with infant outcomes iii. Strategies and Activities: Collaborations: To maximize opportunities for Hepatitis B prevention through vaccination, referral for care, and treatment of persons found to have chronic Hepatitis B infection, this FOA encourages Perinatal Hepatitis B Prevention Program collaborations and service integration as a program imperative of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Such collaborations can increase efficiency, reduce redundancy, eliminate missed opportunities, and improve outcomes through the use of shared data and services. a. With CDC-funded programs: Applicants should create and build upon internal health department collaborations to improve identification of Hepatitis B-infected pregnant women; screen their household and sexual contacts for Hepatitis B and complete vaccination of susceptible persons; refer persons with chronic Hepatitis B infection for care and treatment; and report infants, household, and sexual contacts with chronic Hepatitis B infection to the National Notifiable Diseases Surveillance System. b. With organizations external to CDC: Opportunities for collaboration with non-CDC organizations will be encouraged; non-CDC organizations may include commercial laboratories and health system

The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers.  The term "avant-garde" is used to describe highly innovative approaches that have the potential to be transformative.  The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others.  The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

This Funding Opportunity Announcement (FOA) encourages research to understand and promote adherence to antiretroviral (ARV) regimens for HIV treatment and prevention. Studies addressing pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) are the foci of this FOA. The overarching emphasis is on the development of feasible interventions to improve and sustain PrEP or ART adherence which could be rapidly implemented in clinical, community, and policy environments to improve HIV treatment and prevention outcomes.  

The purpose of this FOA is to conduct research to assess the impact of policies and administrative practices on the inappropriate prescribing or abuse of prescription opioid analgesics. This funding will support projects that: (1) evaluate the impact of current legislation that requires state oversight of pain management clinics or sets out registration, licensure, or ownership requirements for such clinics, or (2) evaluate the impact of formulary management and benefit design strategies used by public or private insurers and pharmacy benefit managers (e.g., quantity limits, step therapies, preferred drug lists, prior authorization, tiered formularies, and drug utilization review programs) that are applicable to all beneficiaries, not just those identified as abusing drugs or engaged in fraudulent activity.

The goal of this Funding Opportunity Announcement (FOA) is to support novel basic and translational research projects that focus on the biology of residual oral reservoirs for HIV and opportunistic oral pathogens.These studies will advance our understanding of the immunologic, pathogenic, molecular and cellular mechanisms important for eliminating latently persistent, reactivation competent HIV and other opportunistic pathogens from residual oral reservoirs.Specifically, this FOA encourages studies on: 1) purging and abolishing these pathogens after using Highly Active Anti-Retroviral Therapy (HAART) to induce cytopathic killing and immunoclearance; or 2) developing alternative strategies that directly eliminate latently infected cells in which HAART resistant HIV and opportunistic pathogens persist in oral reservoirs.

The goal of this Funding Opportunity Announcement (FOA) is to support novel basic and translational research projects that focus on the biology of residual oral reservoirs for HIV and opportunistic oral pathogens.  These studies will advance our understanding of the immunologic, pathogenic, molecular and cellular mechanisms important for eliminating latently persistent, reactivation competent HIV and other opportunistic pathogens from residual oral reservoirs.  Specifically, this FOA encourages studies on: 1) purging and abolishing these pathogens after using Highly Active Anti-Retroviral Therapy (HAART) to induce cytopathic killing and immunoclearance; or 2) developing alternative strategies that directly eliminate latently infected cells in which HAART resistant HIV and opportunistic pathogens persist in oral reservoirs.

The purpose of this funding opportunity announcement (FOA) is to support mechanistic clinical studies aimed at understanding the impact of arts-based approaches in palliative care for symptom management. This FOA is intended to support mechanistic clinical studies to provide an evidence base for the use of the arts in palliative care for symptom management. The objective is to understand the biological, physiological, neurological, psychological, and/or sociological mechanisms by which the arts exert their effects on symptom management during and throughout the palliative care continuum. The goal is for the research supported under this FOA to develop an evidence-base that could be used as a basis for the uptake of arts-based therapies in palliative care settings, among individuals across the lifespan, with a wide variety of serious chronic conditions and their accompanying symptoms. This FOA is not intended to determine efficacy or the comparative effectiveness of interventions, or to assess interventions designed to treat the underlying cause of a particular disease state.